Abstract
The identification and characterization of the inducible form of cyclooxygenases (COX-2) stimulated the investigations to develop efficient, non-steroidal anti-inflammatory drugs (NSAIDs) with reduced side effects (essentially gastro-intestinal toxicity) compared to classical NSAIDs. This review focuses on the chemical and pharmacological properties (pre-clinical data) of marketed COX-2 inhibitors.
Keywords: cox-2 inhibitors, cox-2 selectivity, pre-clinical data
Mini-Reviews in Medicinal Chemistry
Title: First and Second Generations of COX-2 Selective Inhibitors
Volume: 4 Issue: 6
Author(s): Xavier de Leval, Fabien Julemont, Valerie Benoit, Michel Frederich, Bernard Pirotte and Jean-Michel Dogne
Affiliation:
Keywords: cox-2 inhibitors, cox-2 selectivity, pre-clinical data
Abstract: The identification and characterization of the inducible form of cyclooxygenases (COX-2) stimulated the investigations to develop efficient, non-steroidal anti-inflammatory drugs (NSAIDs) with reduced side effects (essentially gastro-intestinal toxicity) compared to classical NSAIDs. This review focuses on the chemical and pharmacological properties (pre-clinical data) of marketed COX-2 inhibitors.
Export Options
About this article
Cite this article as:
Leval de Xavier, Julemont Fabien, Benoit Valerie, Frederich Michel, Pirotte Bernard and Dogne Jean-Michel, First and Second Generations of COX-2 Selective Inhibitors, Mini-Reviews in Medicinal Chemistry 2004; 4 (6) . https://dx.doi.org/10.2174/1389557043403693
DOI https://dx.doi.org/10.2174/1389557043403693 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glia as a Turning Point in the Therapeutic Strategy of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Synthesis and Anticancer Studies of Novel N-benzyl Pyridazino ne Derivatives
Letters in Drug Design & Discovery Cardiovascular Disease in Patients with Diabetic Nephropathy
Current Molecular Medicine Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells
Current Cancer Drug Targets Nanoparticle Coated Viral Vectors for Gene Therapy
Current Biotechnology Association of Lower Adiponectin Plasma Levels, Increased Age and Smoking with Subclinical Atherosclerosis in Patients with HIV-1 Infection
Current HIV Research Relevance of Postprandial Lipemia in Metabolic Syndrome
Current Vascular Pharmacology Mesalazine Activates Adenosine Monophosphate-activated Protein Kinase: Implication in the Anti-inflammatory Activity of this Anti-colitic Drug
Current Molecular Pharmacology Regulation of Apoptosis and Cell Survival by Resveratrol
Mini-Reviews in Organic Chemistry Major Developments in the Design of Inhibitors along the Kynurenine Pathway
Current Medicinal Chemistry The Therapeutic Potential of PhospholipaseA2 Inhibitors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Mechanisms of Immune Modulation by Mesenchymal Stromal Cells and Clinical Translation
Current Molecular Medicine Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Mitophagy in Carcinogenesis and Tumour Progression- A New Paradigm with Emerging Importance
Anti-Cancer Agents in Medicinal Chemistry Nanotools for the Delivery of Antimicrobial Peptides
Current Drug Targets Spirulina in Health Care Management
Current Pharmaceutical Biotechnology Plant Proteomics and Peptidomics in Host-Pathogen Interactions: The Weapons Used by Each Side
Current Protein & Peptide Science Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review
Current Drug Metabolism RNAi-Based Functional Genomics in Caenorhabditis elegans
Current Genomics